Podcasts about Driver

Not cool, dude!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when one person with a big vision is tasked with building a global learning function from scratch? In this episode, Matt sits down with Akkshada Maniyan, who's turned learning into a strategic superpower at Innova Solutions. From building a global team to creating 88+ in-house courses and 100+ personalized learning paths, she's all about scaling with heart and hustle.

00:00 – AZ October Fest 2025 Announcement 01:11 – Show intro & Ryan Stiles Harris joins the show 04:30 – Reactions to Ryan's first NNRC appearance 08:30 – RC media, controversy, and public perception 15:20 – Creating authentic content vs. chasing views 19:00 – Leaving Horizon & focusing on racing 22:00 – Loyalty to Techno RC and racing confidence 28:30 – Setup talk & how small changes make a big difference 32:00 – Young talent in RC & consistency vs. speed 38:30 – Thoughts on race media and coverage challenges 39:00 – Industry changes: TLR, team strategies, and brand shifts 46:00 – Driver influence on car sales and brand image 52:00 – Reflections on legendary drivers & current form 59:00 – Career advice for young racers & professionalism in RC 1:07:00 – Staying focused & the content creation mindset 1:14:00 – Silly season talk & pick predictions 1:21:00 – Can RC racing go mainstream? 1:28:00 – What race formats and events could help grow RC 1:32:00 – Broadcast ideas for a wider RC audience 1:40:00 – Growth fears & overcoming ego in the industry 1:47:00 – Burnout, motivation, and rediscovering your passion 1:51:00 – How big is RC really? The bubble vs. reality 1:54:00 – Gatekeeping vs. mentorship: growing the hobby the right way 2:01:00 – Final thoughts on content, growth, and the future of RC Ryan Stiles Harris is back! In this episode, we catch up with one of our most popular and thought-provoking guests for a deep conversation about racing, content creation, industry shifts, and the soul of RC. Ryan opens up about his departure from Horizon, why he remains loyal to Techno RC, and how his mindset around racing and content has evolved. We dive into setup nuances, the importance of mental preparation, and how small changes can make a big difference on the track. Ryan also shares his thoughts on young talent in the scene, the role of influencers, and whether RC can truly go mainstream. We also explore the current state of 1/10 and 1/8 racing, the impact of pro driver visibility on brands, and how the RC community can grow without losing its identity. Whether you're a racer, content creator, or long-time hobbyist, this episode is full of honest insight, strong opinions, and real talk about where RC is today—and where it could go next. Ryan's YouTube Channel ; https://www.youtube.com/@RyanHarrisRC

GS#1009 Summary: This week we speak to Marc Bender, Managing Partner for multiple golf companies including Hidden Links Travel, Golfpac Travel, TeeTimes USA, Go Play Golf Card, and Upper Deck Golf. In this episode, Fred and Marc discuss their connection at the Masters, the intricacies of golf course architecture, and the evolution of golf greens. Marc is well connected in the golf industry and has met and played with some of the top names in our sport. He's also traveled extensively to golf courses throughout the world so he's well equiped to discuss the evolution of golf course greens, particularly focusing on the advancements in green speeds and their impact on players. The discussion highlights how technology and agronomy have transformed the game, and how this has affected different types of players.They delve into the debates surrounding historical versus modern courses, and the importance of understanding the nuances of putting on different types of greens. The conversation highlights the passion for golf and the community that surrounds it.Please check out this article about Fred's golf and podcast journey called "A Lifetime On The Air" that was published in the NCGA Magazine (Northern California Golf Association) recently!   Get more when your visit the refreshed golfsmarter.com!Introduce an Upcoming Episode: Receive free gifts for recording a show opening by clicking on "Record Your Show Open Here!" tab on the right side of golfsmarter.com. Watch Daily Video Highlights from Our Interviews: Follow @golfsmarter on Instagram, X, Facebook, TikTok, YouTube daily to see our highlights and helpful insights from our interviews on the podcast. Post a Review: you'll receive three free gifts when you post an honest review about Golf Smarter the podcast.Fill Out a Listener Survey: It only takes a few minutes to fill out our survey, which helps us to better serve your interests in the podcast. You'll receive a free link to Tony Manzoni's video and Justin Tang's summary of Tony's Lost Fundamental on pdf!This episode is brought to you by BreakfastBalls.Golf. Visit BreakfastBalls.Golf for the best quality and pricing on premium used golf balls. Find your favorite brand at half the price of new balls!  Use GOLFSMARTER at checkout for 20% off your order!This episode is brought to you by the Tour Striker Golf Academy. Visit tourstriker.com/TSGA and use the code GOLFSMARTER to get your first month of the Tour Striker GolfAcademy Online free, plus instant access to two bonus courses—'The Recipe for Better Golf' and 'Bombs: How to Consistently Smash the Driver”: a $194 value for free.This episode is brought to you by 5Hour Energy. 5-hour ENERGY Transfusion flavor is available online or in stores. Head to 5hourENERGY.com and order yours today!Check out "Invested in the Game", a new original podcast from Charles Schwab. This podcast is their way of sharing the incredible stories behind the game. Listen now at schwab.com/TheGame or wherever you get your podcasts.This episode is sponsored by Indeed. Please visit indeed.com/GOLFSMARTER and get a $75 SPONSORED JOB CREDIT. Terms and conditions apply.   

A lot has happened in the last 24 hours, including race plans for injured drivers, there are silly season updates, a late model driver faces a lengthy ban, and more. We'll update you today on everything you need to know.

Stupid News 7-22-2025 6am …The Driver was going 111mph to get to Church on time …Florida Man offering Free Golden Showers …The Richardson Ground Squirrel Infestation Destroying a City in North Dakota

In this episode of Elevate Care, host Keri Perez engages in an insightful conversation with Tomya Watt, Chief People Officer at AMN Healthcare, about the evolving role of Chief Human Resource Officers (CHROs). Together, they explore how CHROs have transitioned from transactional roles to becoming strategic, solution-driven partners in the C-suite. The discussion highlights the power of data in driving workforce transformation, the importance of aligning talent strategies with business goals, and how holistic workforce solutions and technology integration can elevate patient care and organizational success.Chapters00:00 The Evolving Role of CHROs06:08 Holistic Workforce Solutions and Technology Integration09:23 Aligning Talent Strategies for Workforce TransformationWant to keep the conversation going?Join Tomya for an upcoming Becker's Healthcare webinar:Turn Workforce Risk Into Enterprise Value: The CHRO Playbook

Are you ever going to text me?This episode takes the form of a giant glass of water.Jason, Jim, and Joseph rattle off some of the worst television and movie superheroes ever made.I'm the Nightmower!!Jason confronts his personal beef with Aquaman.Jim and Joseph come to blows over the Wonder Twins.Jack Nicholas as "The Driver"Jim gives a lesson on the Apache language.Jason gets triggered AGAIN over Madame Web.The Makeup Department couldn't even bother with covering up Shaq's tattoo.What legendary actor was the voice of Nuclear Man?What dollar movie did Joseph ask for a refund?

The Irish Road Haulage Association calling on the Government to remove the driver testing system from the Road Safety Authority. Before, they say “any more damage to the Irish economy is done”. Speaking to Newstalk Breakfast was Brendan Walsh, Chief Operations Officer, Road Safety Authority.

The Irish Road Haulage Association calling on the Government to remove the driver testing system from the Road Safety Authority. Before, they say “any more damage to the Irish economy is done”. Speaking to Newstalk Breakfast was Brendan Walsh, Chief Operations Officer, Road Safety Authority.

In this week's episode, Zoe and Hannah discuss which F1 driver is most likely to share their location with another driver, go to IndyCar, survive the longest on a deserted island, get married next, start a podcast, and have a child who races in F1. It's a fun one!

On episode 864 of WHAT THE TRUCK?!? Thomas Wasson is hosting. We catch up with Todd Waldron, vice president of carrier experience at Truckstop.com and look at their recent driver survey, the role AI is playing for truckers today, and celebrate Truckstop's 30 year anniversary. We also dive into the LTL world by unpacking the Synchro LTL Claims Index and talk with Bill Jackson, Founder and the creator of the index about how folks can use it.  Watch on YouTube Check out the WTT merch store Visit our sponsor Subscribe to the WTT newsletter Apple Podcasts Spotify More FreightWaves Podcasts #WHATTHETRUCK #FreightNews #supplychain Learn more about your ad choices. Visit megaphone.fm/adchoices

Kenny Wallace discusses Denny Hamlin winning at Dover. #kennywallace #nascar #racing #dennyhamlinBrought to you by JEGS! Click here: http://jegs.ork2.net/rQ9Oy5Use Promo Code DEALS To Save Up To 50% OFF Sitewide! ***thumbnail photo by Sean Gardner/Getty Images courtesy of NASCAR Media Shop Doorbusters, Stackable Savings & 1,000's of Deals at JEGS!JEGS has been in business since 1960.Racers selling to racers.Focusing on American Muscle – but also big product line of automotive tools, garage gear & other performance parts.JEGS is well established with racers of all kinds, including the NHRA, bracket racing, circle track & more!Free shipping on orders over $199.Unrivaled expertise from techs.

Ger Hyland, President of the Irish Road Haulage Association, accuses the Road Safety Authority of moving truck and bus driving testers to clear backlogs for cars.

WDAY First News anchors Lisa Budeau, Scott Engen and Lydia Blume break down your regional news and weather for Monday, July 21. InForum Minute is produced by Forum Communications and brought to you by reporters from The Forum of Fargo-Moorhead and WDAY TV. Visit https://www.inforum.com/subscribe to subscribe.

Welcome to the CanadianSME Small Business Podcast, hosted by Kripa Anand, where we explore the technologies and insights transforming industries across Canada. Today, we're focusing on the insurance sector's evolution through the integration of Artificial Intelligence, particularly in underwriting, where AI is helping address efficiency, accuracy, and the challenges of data management.Joining us is Craig Mauchan, Vice President of Insurance Markets at SortSpoke, an AI-powered platform that helps insurance teams streamline complex submissions while keeping underwriters in control. Today, we'll discuss how AI is revolutionizing the industry, addressing the underwriter talent shortage, and enabling smarter, more efficient operations.Key Highlights:1. Demystifying Commercial Underwriting: Craig will explain what most people get wrong about how commercial underwriting works behind the scenes, including some of the key complexities and manual processes involved.2. Common Misconceptions Insurance Companies Have About AI Technology: Craig will discuss some of the common misconceptions that insurance companies have about AI technology, particularly in relation to its application in underwriting.3. Why Insurance Companies Need to Adopt Underwriting Technology: Craig will highlight the most common reasons why an insurance company would need to adopt underwriting technology and the biggest challenges small to mid-sized insurance carriers face when modernizing their operations.4. SortSpoke's “Human-in-the-Loop” AI Approach: Craig will explain SortSpoke's “human-in-the-loop” AI approach and why it's important specifically in the context of insurance underwriting.5. How Technology Can Help Solve the Underwriter Talent Shortage Problem: Craig will discuss how technology, particularly AI-powered platforms like SortSpoke, can help insurance carriers solve the growing underwriter talent shortage problem.Special Thanks to Our Partners:RBC: https://www.rbcroyalbank.com/dms/business/accounts/beyond-banking/index.htmlUPS: https://solutions.ups.com/ca-beunstoppable.html?WT.mc_id=BUSMEWAGoogle: https://www.google.ca/A1 Global College: https://a1globalcollege.ca/For more expert insights, visit www.canadiansme.ca and subscribe to the CanadianSME Small Business Magazine. Stay innovative, stay informed, and thrive in the digital age!Disclaimer: The information shared in this podcast is for general informational purposes only and should not be considered as direct financial or business advice. Always consult with a qualified professional for advice specific to your situation.

Ben and Sam are back for part two of their F1 driver report cards, breaking down who has impressed and who has underdelivered in the first half of the 2025 season. Plus, they dive into the F1 movie, Apple's possible entry into the sport, and answer some listener questions... >>> Don't miss out - limited tickets left for our 2025 LIVE SHOW in Austin TX! ⁠⁠⁠⁠⁠⁠⁠CLICK HERE⁠⁠⁠⁠⁠⁠⁠ to grab yours or for more info!

Stevens Roundtable:  Exciting Changes for Season Eight of the podcast Tim Cicciarelli and Paula Evans as they unveil exciting changes for the eighth season of the Stevens Transport Roadside Radio Podcast. This episode delves into a new dynamic approach to podcasting, allowing timely and interactive interviews with drivers. Discover how they plan to integrate more driver stories, bolster communication, and enhance social media presence. With insights from Paula on the evolving digital engagement, the conversation offers a peek into the podcast's evolution and dedication to capturing authentic experiences from the road. Stevens Transport's Graduate Rotational Program Ryan Cardenas about his journey from an intern to a full-time employee at Stevens Transport. Ryan shares insights from his experience in the graduate rotational program, highlighting his passion for driver management and teamwork. He offers valuable advice for new graduates entering logistics, emphasizing the importance of consistency, assertiveness, and a willingness to learn. The conversation also delves into the family-like culture at Stevens Transport, showcasing how this supportive environment fosters personal and professional growth. Tune in to learn more about Ryan's impactful start in the logistics industry. Become a Team Driver for Stevens Transport Discover the transformative world of team driving with Stevens Transport in this insightful discussion. Learn how driving with a partner boosts efficiency, earning potential, and safety, while allowing for nearly constant travel and the enjoyment of America's stunning landscapes. Understand how federal regulations intersect with teamwork logistics, enabling over 5,500 miles a week. Insights on rest strategies, like bunk bed sleeping arrangements, are shared. Stevens Transport explains the advantages of choosing your driving partner and how this approach can elevate your trucking career. Explore team driving's benefits and start your journey to success now. Earn More/Team Up - https://vimeo.com/1020240977 Stevens Transport News Bulletin - July 2025 Stevens Transport brings you the latest updates on the transportation industry in our Monthly News Bulletin! In this month's bulletin, we thank Cedar Hill Police for visiting and promoting road safety through their demonstrations and celebrate milestone anniversaries with two of our dedicated employees. You can read more about these stories and others in our quarterly Birdseye Newsletter here: https://www.stevenstransport.com/news/ See the video here: https://www.youtube.com/watch?v=XwrlFeqCy6I&t=97s Stevens Transport Employment Resources Pilot/Flying J Rewards App: https://pilotflyingj.com/rewards Become a Driver for Stevens Transport For questions on whether you meet our driver qualifications, please call our Recruiting Department at 1-800-333-8595 or visit: www.stevenstransport.com/drivers/ Stevens Transport 9757 Military Parkway, Dallas, TX 75227 http://www.stevenstransport.com/ http://www.becomeadriver.com/ Driver Recruiting: 1-800-333-8595.  Apply Here: https://intelliapp2.driverapponline.com Paragon Leasing Technician Careers: https://www.stevenstransport.com/careers/fleet-maintenance-jobs/ Stevens Transport on Facebook: https://www.facebook.com/StevensTransport

A career-ending injury led John Rotche, a former Michigan football player, to deliver pizzas for Domino's founder, Tom Monaghan, and ultimately to a 35-year franchise empire. In this candid conversation, the IFA award winner shares how following systems over ego has built multiple national brands, such as DUCTZ and Title Boxing Club, why mentorship matters more than innovation, and how a recent car accident led him to FranPath Consulting. Two franchise veterans reveal the counterintuitive wisdom behind sustainable business success and why the proven path consistently outperforms the glamorous one.

The moment we have all been waiting for, the Wallabies play their first Test against the British and Irish Lions at Suncorp Stadium on Saturday, 19 July.OTR is joined by Scrumbags Pod member Lachie to break down what the two sides say about playstyles, tactics, and in whose favour some of the match-ups are favouring.Don't forget to subscribe for more rugby previews and reviews!Find more of John's work at:Youtube - https://www.youtube.com/@OfftheRuckRugbypass - https://www.rugbypass.com/contributors/john-ferguson/The Roar - https://www.theroar.com.au/author/johncsferguson3561/OUR LINKSWallaby Shop - https://wallaby.sjv.io/WyRyVGLinktree - https://linktr.ee/Scrumbags_rugbyInstagram - https://www.instagram.com/scrumbagsrugby/Twitter/X - @scrumbagsrugby Hosted on Acast. See acast.com/privacy for more information.

GS#402 September 17, 2013 “You'll become a ‘golfer' when learning becomes more important than the outcome of your shot.” Be prepared to have your normal perceptions of improvement challenged, Fred Shoemaker of Extraordinary Golf talks about his DVD.Please check out this article about Fred's golf and podcast journey called "A Lifetime On The Air" that was published in the NCGA Magazine (Northern California Golf Association) recently!   Get more when your visit the refreshed golfsmarter.com!Introduce an Upcoming Episode: Receive free gifts for recording a show opening by clicking on "Record Your Show Open Here!" tab on the right side of golfsmarter.com. Watch Daily Video Highlights from Our Interviews: Follow @golfsmarter on Instagram, X, Facebook, TikTok, YouTube daily to see our highlights and helpful insights from our interviews on the podcast. Post a Review: you'll receive three free gifts when you post an honest review about Golf Smarter the podcast.Fill Out a Listener Survey: It only takes a few minutes to fill out our survey, which helps us to better serve your interests in the podcast. You'll receive a free link to Tony Manzoni's video and Justin Tang's summary of Tony's Lost Fundamental on pdf!This episode is brought to you by BreakfastBalls.Golf. Visit BreakfastBalls.Golf for the best quality and pricing on premium used golf balls. Find your favorite brand at half the price of new balls!  Use GOLFSMARTER at checkout for 20% off your order!This episode is brought to you by the Tour Striker Golf Academy. Visit tourstriker.com/TSGA and use the code GOLFSMARTER to get your first month of the Tour Striker GolfAcademy Online free, plus instant access to two bonus courses—'The Recipe for Better Golf' and 'Bombs: How to Consistently Smash the Driver”: a $194 value for free.This episode is brought to you by 5Hour Energy. 5-hour ENERGY Transfusion flavor is available online or in stores. Head to 5hourENERGY.com and order yours today!Check out "Invested in the Game", a new original podcast from Charles Schwab. This podcast is their way of sharing the incredible stories behind the game. Listen now at schwab.com/TheGame or wherever you get your podcasts.This episode is sponsored by Indeed. Please visit indeed.com/GOLFSMARTER and get a $75 SPONSORED JOB CREDIT. Terms and conditions apply. This episode is sponsored by Indeed. Please visit indeed.com/GOLFSMARTER and get a $75 SPONSORED JOB CREDIT. Terms and conditions apply.    

FLORIDA FRIDAY - Florida woman bear maced a driver that ran over a chicken. Florida receptionist overpaid $400k by her employer by mistake and she spent it. Floridaman arrested with stolen motorcycle and meth hidden in his anal cavity. Florida flesh eating bugs have killed four this summer. // Weird AF News is the only daily weird news podcast in the world. Weird news 5 days/week and on Friday it's only Floridaman. SUPPORT by joining the Weird AF News Patreon http://patreon.com/weirdafnews - OR buy Jonesy a coffee at http://buymeacoffee.com/funnyjones Buy MERCH: https://weirdafnews.merchmake.com/ - Check out the official website https://WeirdAFnews.com and FOLLOW host Jonesy at http://instagram.com/funnyjones

We were reintroduced last week to Leopold Ruddock and were amazed at his talent and tenacity to become the fastest track athlete in his class and set records that still stand at the school of his homeland in Jamaica. Today, we hear how that same talent and tenacity fueled his rise to become a nationally top-ranked driver in his new homeland of America. You simply can't keep this man down. Driveaway's Leo-the-Lion is driven to succeed, and he does it with class. As you'll hear in today's conversation, he carries a deep respect for the craft and for the people he meets along the way. Leo Ruddock certainly has our respect, and we're pleased to have him back on the show for today's episode of the Six-Figure Trucker. Show Notes: John teases the upcoming video release for the Six Figure Trucker! (0:28)Following his Lady to America (2:50)Leo overcomes odds on his way to his career behind the wheel (5:48)Becoming the #1 Driver in the Country! (13:51)Sage advice from a 36 year Veteran of Trucking (17:37) The Six-Figure Trucker is a weekly podcast about driveaway trucking brought to you by Norton Transport. For more information or to subscribe, please visit Six-FigureTrucker.com.

For the last 12 years, our Driver Development Centers have helped shape our culture of safety. From backing to turning to pre-trips and everything in between, Gary Craighead and the other instructors have taken pride in developing one of the safest driving groups in the industry. Gary and Director of Safety and Compliance Jason Bolton join David Broyles to highlight this unique opportunity we provide to our driving force on this episode of From the Driver's Seat.

**PETERBILT** Skillex 2026 CUSTOM TRUCK SHOWCASE! #truckshowcase #Peterbilttrucks #customtrucks #featuredtruck Peterbilt fans! We're taking a closer look at the incredible Skillex 2026 custom truck, and trust us, you won't want to miss it! From its sleek design to its powerful performance, this truck is a real showstopper. Whether you're a truck enthusiast or just love all things Peterbilt, this episode is for you! So, sit back, relax, and get ready to feast your eyes on this stunning custom ride. WATCH THE VIDEO ON THE TRUCK HERE Chrome Supply Warehouse has the best selection of chrome and truck parts in Ontario Canada. Located in Belleville Ontario on the North side of the Highway with lots of truck parking. Stop in for a break or to check on their Deal of the day. Learn more online at www.chromesupplywarehouse.com    This episode is sponsored by Bison Transport with many opportunities for truck drivers in their fleet across Canada. At Bison – they put Safety First Bison's “Right to Decide” Policy gives every Driver their ultimate protection. Drivers make the final decision if it is safe to drive and Bison actively encourages Driver's use of this policy.    You can learn more about Bison and the opportunities available at www.bisondriving.com   or call 1-800-527-5781 @BisonTransport #bisontransport   About the Podcast The Lead Pedal Podcast for Truck Drivers helps truck drivers improve their truck driving careers, trucking businesses as owner operators, CDL skills, find trucking jobs, and offer trucking tips. Learn about the trucking benefits and salaries as a professional truck driver through interviews and tips related to the North American Trucking Industry. The Lead Pedal Podcast is a Canadian based trucking podcast focused on trucking in Canada. LISTEN TO THE PODCAST- The show is available at www.theleadpedalpodcast.com , Apple Podcasts, Spotify, iHeartradio, SoundCloud, and other popular podcast platforms. Thanks for listening JOIN THE LEAD PEDAL PODCAST FAN CLUB  www.LeadPedalFanClub.com  LISTEN TO LEAD PEDAL RADIO at www.LeadPedalRadio.com  The Lead Pedal Podcast for Truck Drivers talks all things trucking for people in the transportation industry helping them improve their business and careers. Interviews with industry professionals and truck drivers, trucking information, and other features on the industry are meant to be helpful for truck drivers and those in transportation. The Lead Pedal Podcast for Truck Drivers has main episodes released every Monday, Wednesday, and Friday with bonus material on other days. You can learn more about the host and show on our website and make sure to SUBSCRIBE to the show on your favourite podcast platform. www.theleadpedalpodcast.com  What does The Lead Pedal Podcast mean? The Lead (pronounced - Led) stands for acceleration or fast-track of your career or business. It is a play on words and we certainly are not here promoting speeding in the industry. We are hoping this information will help you become a professional driver faster than if you didn't know about many of these topics. Are you enjoying the show? If so we would appreciate you leaving us a rating and review on your favourite podcast platform. www.theleadpedalpodcast.com  Join The Lead Pedal Fan Club where are loyal fans get first chance at specials, discounts on merchandise and much more.The club is free to join and you can learn more at www.theleadpedalfanclub.com   

• Hyundai IONIQ 9 Launch: Hyundai debuts its new IONIQ 9 electric SUV, positioning it as a premium, spacious, tech-rich executive vehicle. • Alfa Romeo Junior: Alfa Romeo's new compact SUV, the Junior, brings hybrid and electric options to Australia • HERE-SBD EV Infrastructure Report: A report shows uneven progress in EV charging across global regions • EV Market Trends in Australia: EV sales in Australia are growing, • Škoda EV Ad Campaign: Škoda UK's campaign tackles EV stereotypes. • Driver Assistance and Distraction: • AI Monitoring in Fleets: AI-based in-vehicle monitoring aims to coach drivers • Transport Modelling & AI Transparency: Avoiding “black box” decision-making. • Mobility Scooter Accessibility: Listeners share real-world challenges with scooter portability • Hyundai Santa Fe Petrol Road Test: The petrol-only Santa Fe offers solid performance and practicality.

Ben Hogan's new PTx LST driver is built for higher speed players who need launch and spin control. Not many direct to consumer brands are able to offer something this but Ben Hogan did a really good job. The looks are solid and classic but the performance is very good. Flatter trajectory and lower spin, but there is still some forgivness built in!

Dr. Lyudmila Bazhenova is back on the podcast to discuss the latest update of the living guideline on therapy for stage IV NSCLC without driver alterations. She shares the studies the Expert Panel reviewed in the first- and second-line settings, including NIPPON, HARMONi-2, and DUBLIN-3. Although these studies do not impact the existing guideline recommendations, Dr. Bazhenova provides context and comments on ongoing trials that will influence the next iteration of the living guideline. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01062 Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Lyudmila Bazhenova from University of California San Diego Moores Cancer Center, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you back on the show today, Dr Bazhenova. Dr. Lyudmila Bazhenova: It's my pleasure to be here. Brittany Harvey: And then before we discuss this guideline update, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Bazhenova, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into the content here, Dr. Bazhenova, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer without driver alterations is updated on an ongoing continuous basis. So what prompted this latest update to the recommendations? Dr. Lyudmila Bazhenova: Living ASCO guidelines are designed to keep pace with rapidly evolving evidence that impacts treatment of our patients with lung cancer. As a committee, we are tasked with regular review of the published literature and determine if the new data warrants changes to existing recommendations. So in this recently published update, we evaluated new trials related to treatment of patients with metastatic lung cancer without driver alterations. Brittany Harvey: Excellent. Thank you for that explanation of the process. So, you just mentioned that the panel reviewed new trials for this update. So, which particular updated evidence did the panel review on first-line treatment options for patients with good performance status across histology and PD-L1 expression status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: For the first-line treatment option for patients without driver alterations, two studies met our criteria for review. One was the NIPPON trial from Japan, the second was the HARMONi trial. None of those two trials resulted in change in our guidelines, but I think they are giving us some additional information that would be useful for the way we treat patients with non–small cell lung cancer without driver alterations. For example, if we take those patients, we currently have several treatment options as a first line. One is monotherapy immunotherapy. You can give pembrolizumab as an example, and that was based on the KEYNOTE-024 and KEYNOTE-042 trials. Then we have a platinum doublet plus immunotherapy, and there are several trials that did that pathway. And then we have also an option of giving our patients dual IO immunotherapy combination, such as CheckMate 9LA and POSEIDON. At this point, we do not have any randomized trials comparing those three treatment modalities head-to-head. And the NIPPON trial was interesting to us because it was the first trial to compare CheckMate 9LA regimen, which is again, dual immunotherapy plus chemo, versus KEYNOTE-189 or KEYNOTE-407, which is a chemotherapy plus immunotherapy. And as a result of the study, while chemotherapy plus ipilimumab-nivolumab led to numerically higher overall survival, the difference was not statistically significant. And what is concerning in that trial is that we saw a higher number of treatment-related death occurring in nivolumab and ipilimumab arm compared to the pembrolizumab-chemotherapy arm. As a matter of fact, the trial was terminated early because of the increased risk of death. If you look at the treatment-related death in CheckMate 9LA, the 9LA study reported the treatment-related death to be 2%, and then in the NIPPON trial, the treatment-related death was 7%. Why is that happening? It's really difficult to say. The study was done in Japan. Maybe there is some pharmacogenomic differences between global population and Japan population. But certainly the higher rate of adverse events needs to be taken into account. Another interesting thing about this trial is that it did not show any differences in a subset analysis for patients with squamous histology as well as PD-L1 negative tumor. So while this does not change our current guidelines and CheckMate 9LA treatment still remains an appropriate treatment option, it kind of raises the possibility that this combination could be associated with a higher toxicity. And we do have a randomized US-based trial that is ongoing, and we are hoping that eventually we will be able to answer that question after the trial will be completed. The second trial we reviewed is HARMONi-2. So HARMONi-2 was a randomized, double-blind study which is conducted primarily in China, looking at bispecific PD-L1 and VEGF antibody called ivonescimab. And that took patients who were PD-L1 positive, as defined as more than 1% expression, and patients were randomized to pembrolizumab versus bispecific ivonescimab. And the study was positive. It showed improvement in median progression-free survival of 11 months versus almost 6 months in bispecific versus pembrolizumab. There were, however, higher grade 3 events in the ivonescimab arm. At this point, we are not changing our recommendations because this trial was done in an ex-US population, and we are awaiting a similar trial ongoing in the United States before we change recommendations and decide if ivonescimab needs to be included in our guidelines. Brittany Harvey: This context is very helpful when clinicians think through the data behind these options. And it's important that the panel reviews this evidence, even if it doesn't prompt a change to the recommendations. And we'll await results of those trials that you mentioned to further inform this guideline. So then beyond those studies for first line, what updated evidence did the panel review for second-line and subsequent treatment options for patients with good performance status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: So for second line, only one trial met the criteria, and that was DUBLIN-3. DUBLIN-3 is a phase 3 single-blind randomized trial comparing docetaxel versus docetaxel plus plinabulin. And the study enrolled patients with second or third line. They have to have had platinum-based chemotherapy and progressed. Plinabulin is an interesting compound. It's a small molecule tubulin binder that prevents polymerization of tubulin and appears to impact dendritic cell maturation and T-cell activation. This study enrolled 559 patients, randomly assigned them to two groups. And one important information about this study is that was a study that was envisioned before immunotherapy became a standard mainstream treatment for first-line therapy. And only 20% of patients had prior PD-1 exposure. So therefore, the results of that study need to be taken into context of this population no longer existing in the United States because we use PD-L1 inhibitors in the first line. And we saw that interesting in the plinabulin arm had lower rates of neutropenia but higher rates of serious adverse events. And at this point, we are not changing our guidelines for mainly two reasons. Number one, low number of patients that received prior treatment with first-line immune checkpoint inhibitors, as well as a modest overall survival benefit of this trial. Brittany Harvey: Understood. I appreciate you describing that study as well and why that evidence didn't prompt a change to those particular recommendations. So then, what should clinicians know as they implement this living guideline, and how does this new evidence impact clinicians and patients? Dr. Lyudmila Bazhenova: At this point, none of the studies that we reviewed resulted in a change in guidelines. We are still waiting for more global results from some of the studies that I highlighted. It shows that there's still a lot of questions we need to be answering in those patients. And I'm hoping that with future clinical trials, we will be able to definitively maybe recommend one treatment over another. But at this point, all the treatments that I mentioned before remain appropriate for patients with stage IV non–small cell lung cancer without driver alterations. Brittany Harvey: Definitely. And then you just mentioned that there's still a lot of outstanding questions in this field. You've mentioned a couple different studies where we're awaiting evidence. Beyond those that you already mentioned, what is the panel examining for future updates to this living guideline? Dr. Lyudmila Bazhenova: Right now, our next task is to come up with a full guidelines update. ASCO have certain rules for the guidelines committee members. And so we are gearing for a full guideline update, which hopefully will be ready by the end of 2025. Brittany Harvey: Excellent. We'll look forward to that full update of the living guideline, and we'll still await results of these ongoing trials to further inform this living guideline. So I want to thank you so much for your work to rapidly and continuously update this living guideline, and thank you for the time today, Dr. Bazhenova. Dr. Lyudmila Bazhenova: My pleasure. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Dr. Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations. He discusses the new evidence for NSCLC with EGFR mutations and NRG1 fusions and how this impacts the latest recommendations from the panel. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01061 Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you here today, Dr. Reuss. Dr. Joshua Reuss: Thank you. Happy to be here. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So to dive into what we're here today to talk about, Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer with driver alterations is updated on an ongoing basis. So what prompted this latest update to the recommendations? Dr. Joshua Reuss: Yes, thank you. It's very important that we have living guidelines that are continuously updated. We obviously don't live in a static environment where things are non-changing, and we really need to apply the most up-to-date and current evidence to treat our patients with the most effective strategies, the most groundbreaking strategies. And so to have guidelines that can be disseminated, particularly these ASCO guidelines, to treating providers is incredibly important. So, with any of these updates, we review ongoing studies, published work, for the quality of evidence to see if it's something that warrants making adjustments to our guidelines or at least incorporating the information so that providers can review it and incorporate this into their own personal decision-making. So in this particular update, we reviewed evidence particularly pertaining to EGFR-mutated non–small cell lung cancer and non–small cell lung cancer harboring an NRG1 fusion. Brittany Harvey: Yes, certainly there's a lot of new evidence in the advanced non–small cell lung cancer field, and so we appreciate the panel's continuous review of this evidence. So then you just mentioned two separate areas where the panel reviewed new evidence. So starting with that first one, what updated evidence did the panel review on first-line treatment options for patients with EGFR alterations, and how did this impact the recommendations? Dr. Joshua Reuss: Yes, so advanced EGFR-mutated non–small cell lung cancer, at least with classical activating alterations - that is our exon 19 deletions and our exon 21 L858R mutations - is something that's really evolved rapidly in the last few years. You know, for many years, we basically, for the frontline treatment setting, were saying, "Okay, we have a targeted therapy, osimertinib. We're going to give that, and we're going to see what effect we can get out of that," with, you know, a median time of duration of treatment response averaging around 18 months, knowing that there are some that that's a lot longer and some that are a lot shorter. But recently, we've seen a lot of data emerging on combination strategies. The guideline has already been updated to incorporate two of these combinations: osimertinib with chemotherapy based off of the FLAURA2 trial, and then the combination of amivantamab with lazertinib based off of the MARIPOSA trial. And that was data on progression-free survival that was published and led to those particular recommendations. Now, more recently, we've seen data come out in smaller, randomized studies for other combinations. And more recently, we reviewed the RAMOSE study. So this was a phase II, open-label, randomized trial for patients with tyrosine kinase inhibitor–naive and really, treatment-naive advanced EGFR-mutated non–small cell lung cancer harboring one of these two classical EGFR alterations, randomized to either osimertinib alone or osimertinib with the combination of ramucirumab, which is an anti-VEGF agent. There's been a lot of data, preclinical and clinical, for the role of VEGF blockade, particularly in EGFR-mutated non–small cell lung cancer, so exploring the combination of this for synergy in the frontline setting really made a lot of sense. So again, this was a phase II trial that randomized patients prospectively to one of these two regimens. The population here is really what we typically see with EGFR-mutated non–small cell lung cancer, predominantly a younger population - median age on this study was 65 - predominantly female - 71% female - and predominantly nonsmokers. Now, what this study showed was that at a median follow-up of 16.6 months, the progression-free survival favored the combination arm with a median progression-free survival of 24.8 months with the combination of osimertinib plus ramucirumab versus 15.6 months for osimertinib alone, for a hazard ratio of benefit of 0.55. The landmark one- and two-year endpoints for progression-free survival also favored the combination arm, and response rates were relatively comparable between groups, with overall adverse events being more frequent in the combination group, specifically high blood pressure, proteinuria, and epistaxis, which are our common adverse events related to VEGF-blocking agents. So, it's good to see data in this space. Now, of note, though, this was a phase II study, so not a phase III level of evidence. In addition, when looking at the population, this was a randomized, multicenter study, but it was a US-only population. There was also some imbalance in the number of visits between arms, so the combination arm was seen more frequently than the arm that got osimertinib alone. Now, the imaging assessments were no different, but obviously this could lead to potential confounding, at least in timing of awareness of potential side effects and and things being brought to the attention of investigators. So very promising data here, but because, you know, of this being a phase II study, this actually led to no changes in the guideline at this time. Brittany Harvey: Understood. Yes, as you mentioned prior, it's important to understand the full body of evidence and to review the trials even when it doesn't impact the recommendations. Dr. Joshua Reuss: And I will say that, you know, there is an ongoing phase III study looking at a very similar combination. It's the phase III ECOG-ACRIN trial of the combination of osimertinib plus bevacizumab versus osimertinib alone in this specific population. So, you know, I think we will see phase III–level data for a combination of VEGF with osimertinib, but again, promising phase II data that did not lead to a change in the recommendation at this time. Brittany Harvey: Absolutely. We'll look forward to that ongoing trial to learn more about combination in this patient population. So then moving to that second patient population that you mentioned earlier where the panel reviewed evidence, what is the updated evidence and recommendation for patients with NRG1 fusions? Dr. Joshua Reuss: Yeah, so this was an exciting update that we made more recently with this unique iteration of the living guidelines. So, NRG1 fusions, this is perhaps a newer kid on the block in terms of driver alterations that has been known to be identified in non–small cell lung cancer among other solid tumors. It is very rare, occurring in less than 1% of solid tumors, but something that we know is a unique oncogenic pathway that can lead to oncogenesis and cancer development, including in non–small cell lung cancer. So up until now, unfortunately, there have not been targeted therapies that target this unique alteration. It's somewhat different than other driver alterations where there's a top-level signaling change in a protein. This is more of a ligand alteration that then alters, that then enables activation of more classical pathways, but again, through upregulation of a unique ligand. So a slightly different pathway but something that we know should be able to be targeted to promote patient survival for those with NRG1 fusions. So the therapy here is a therapy called zenocutuzumab. It's an IgG1 bispecific antibody against HER2 and HER3. So it prevents the downstream dimerization and signaling that occurs as a result of this NRG1 fusion and upregulation of the NRG1 signal. This was, as you can imagine with a rare alteration, a large phase II registrational study that examined this in advanced solid tumors containing the NRG1 fusion. This is the NRG1 registrational trial. And this study enrolled patients with advanced solid tumors who had progressed on prior therapy. Patients were treated with zenocutuzumab 750 milligrams IV every two weeks. Among 158 response-evaluable solid tumor patients, the response rate was 30%, median duration of response of 11.1 months, and a median progression-free survival of 6.8 months. Now, in those with non–small cell lung cancer, that made up 93 response-evaluable patients, very similar outcomes there: a response rate of 29%, median duration of response of 12.7 months, and a median progression-free survival of 6.8 months. This therapy did appear to be well tolerated. The most common higher-grade emergent side effects - grade 3 or higher - were anemia occurring in 5% and elevated liver numbers occurring in 3%. So this is a subsequent-line study, so this led to the updated recommendation that clinicians may offer zenocutuzumab in the subsequent-line setting for patients with advanced non–small cell lung cancer who harbor NRG1 fusions. So I think this does speak toward the incredible importance of next-generation sequencing and molecular testing for patients, particularly to include testing that looks at the RNA. These large fusions can sometimes be very challenging to detect on DNA sequencing platforms alone, so it's important to, if you have a high level of suspicion for an alteration like this, perhaps some of the mucinous adenocarcinomas where it's been challenging to find a driver alteration, and it's someone who is a never-smoker, really would want to include molecular testing that assesses the RNA level and not just the DNA. Brittany Harvey: Absolutely. It's important to have all the biomarkers available so that clinicians are able to use that to inform their decision-making. So then, given these changes in the guideline, what should clinicians know as they implement this latest living guideline update? And how do these changes impact patients? Dr. Joshua Reuss: Yeah, I think talking in reverse order of what we just discussed here, there is a new guideline update for NRG1 fusions. So I think making sure that that's being evaluated, that clinicians are testing for that and really looking for that result that should be incorporated in in most next-generation large sequencing assays to get that result, but it's very important that that is not overlooked now that we do have a therapy that's available in the subsequent-line setting, though it is important to note that patients with NRG1 fusions, at least the limited data that there is suggests that the efficacy to standard chemoimmunotherapy regimens is overall poor. So physicians unfortunately might be facing this question for second-line therapy in patients with NRG1 fusions sooner rather than later. For the former, for EGFR-altered non–small cell lung cancer and how do we incorporate VEGF-containing regimens into these patients? Our guideline top-level update did not change based off of review of this new study, but it's important for clinicians to know what other combinations may exist. You know, there are phase III studies looking at this combination in the frontline setting. And of course, there is data on other bispecific molecules that incorporate VEGF in the subsequent-line setting, particularly a combination that includes the VEGF/PD-1 bispecific antibody ivonescimab that's being studied in the HARMONi-A trial for patients with EGFR-mutated advanced non–small cell lung cancer, for which we hope to get some more definitive data in the coming months. Brittany Harvey: Definitely. And then you've just mentioned a few ongoing trials where we're looking for evidence to inform future updates. But thinking beyond that, into the future, what is the panel examining for future updates to this living guideline? Dr. Joshua Reuss: It's a very exciting time to be in the world of treating advanced non–small cell lung cancer, particularly patients with driver alterations, because there is so much evolving data that's changing our practice in real time, again highlighting the importance of these living guideline updates. I'd say there's many things that we're excited to see. You know, a lot of the combination regimens in EGFR-mutated non–small cell lung cancer for which there are approvals and current recommendations in our guideline, particularly osimertinib plus chemotherapy and amivantamab plus lazertinib - those are the two approved combination strategies in the front line - we are now seeing the emergence of overall survival data for those combinations. So obviously that is something that's going to be very important for the committee to review and incorporate into guideline updates. There are several new therapies coming down the road for other driver populations. We recently saw an approval for taletrectinib for ROS1 fusion–positive non–small cell lung cancer, so it's going to be important that the committee reviews the data and the publications regarding that therapy. And then there are other novel therapies that we're looking to see updated data on. There are multiple antibody-drug conjugates, which take the potent power of a chemotherapy molecule and attempt to make that targeted with an antibody targeting to a unique feature on the cancer cell. And there are several antibody-drug conjugates that are in development at various levels of promise in this space, particularly in EGFR-mutated non–small cell lung cancer, and I anticipate seeing some emerging data for that coming up in the near future as well. So really, lots to be excited in the space and lots for our committee to review to give guidance on so that these patients can really receive the top-level care wherever they are being treated in the country and throughout the world. Brittany Harvey: Yes, we'll await this new data to continue to provide optimal options for patients with stage IV non–small cell lung cancer with driver alterations. So, Dr. Reuss, I want to thank you so much for your work to rapidly and continuously update and review the evidence for this guideline and thank you for your time today. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available on the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Rashid Galadanci, CEO and co-founder, Driver Technologies, discusses how connected car technology and telematics are transforming insurance by improving underwriting accuracy, speeding up claims and reducing fraud.

Comment on the show?..send me a text!

Fresh out of 2025 Goodwood Festival of Speed, Ben and Sam are here giving each driver on the 2025 grid their mid-season report cards! They also discuss Pirelli's divisive new tyre and Alex Dunne's impressive McLaren debut, before a quick round of Pump the Brakes... >>> Don't miss out - limited tickets left for our 2025 LIVE SHOW in Austin TX! ⁠⁠⁠⁠⁠⁠CLICK HERE⁠⁠⁠⁠⁠⁠ to grab yours or for more info!

O.C. Driver's and the convertible society in 2025 // Whip Around: How many days are in one million and one billion seconds? // Jet Write-offs & third-world problems // Mark's hat tag 

Has Steam's new publishing rule given third-party electronic payment processors control over game listings? Casting has been announced for the Legend of Zelda movie. We pick our fantasy cast. Seagate's HAMR-based hard drives are now available to consumers, with 30TB models going for $600. And does Razer's new Core X V2 signals a new start for eGPUs? Starring Sarah Lane, Tom Merritt, Scott Johnson, Roger Chang, Joe. To read the show notes in a separate page click here! Support the show on Patreon by becoming a supporter!

Welcome to Show Me The Money Club live show with Sergio and Chris Tuesdays 6pm est/3pm pst.

Fresh out of 2025 Goodwood Festival of Speed, Ben and Sam are here giving each driver on the 2025 grid their mid-season report cards! They also discuss Pirelli's divisive new tyre and Alex Dunne's impressive McLaren debut, before a quick round of Pump the Brakes... >>> Don't miss out - limited tickets left for our 2025 LIVE SHOW in Austin TX! ⁠⁠⁠⁠⁠⁠CLICK HERE⁠⁠⁠⁠⁠⁠ to grab yours or for more info!

Skinwalkers are so much scarier than TikTok wants you to think they are. Subscribe on Patreon to support The Lore Lodge for just $1 per month! https://patreon.com/thelorelodge Wear the Lodge from https://www.bunkerbranding.com/pages/the-lore-lodge Get our new signature coffee blend at https://tablowroastingco.com/products/the-lore-lodge-mt-pocono-perk Shop our online retail store, find other content, and buy our partners' products at https://linktr.ee/theaidanmattis Discord: https://bit.ly/jointhelodge Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today Lil' Lo and Big Shot Shae are joined by entrepreneur and creative Amir Driver! Join the class as they discuss the Made in Norfolk brand, making a difference where you are, social experiments, what Love Island is, and more! Follow Our Guest On IG: @amirdrivermadeEmail for advice / to be featured: LetMeStayFocused@gmail.com Follow Our Hosts:@lilloworldwide@bigshotshae**DISCLAIMER: THIS IS A COMEDIC PODCAST** Scenarios and responses from this show should be taken with a grain of salt. In other words, this is all a joke. Unless otherwise noted, any similarity to actual persons, living or dead, or actual events, is purely coincidental.The views and opinions expressed by guests / classmates are those of the guest / classmate and do not necessarily reflect the official policy or position of Let Me Stay Focused: The Podcast. Any content provided by our guests / classmates are of their opinion and are not intended to malign any religion, ethnic group, club, organization, company, individual or anyone or anything.

GS#1008 Summary: This week we speak to Jason Chambers, a golf instructor at Onyx Golf Academy in Orange County, California. We discuss the rise of simulator golf, its benefits and challenges, and how it caters to the needs of golfers in a densely populated area. The conversation also touches on the importance of golf instruction, decision-making in golf, and the potential of new formats like TGL to attract a younger audience to the game. We also explore the social aspects of simulator golf and how it can serve as a fun alternative to traditional golf, while also emphasizing the need for diverse instructional methods in teaching the game. Jason shares his viewpoint on the complexities of golf instruction, emphasizing the importance of understanding individual needs and the pitfalls of modern swing techniques. He highlights the necessity of practice and commitment for improvement, the joy of teaching average golfers, and the significance of learning through personal experience. Please check out this article about Fred's golf and podcast journey called "A Lifetime On The Air" that was published in the NCGA Magazine (Northern California Golf Association) recently!   Get more when your visit the refreshed golfsmarter.com!Introduce an Upcoming Episode: Receive free gifts for recording a show opening by clicking on "Record Your Show Open Here!" tab on the right side of golfsmarter.com. Watch Daily Video Highlights from Our Interviews: Follow @golfsmarter on Instagram, X, Facebook, TikTok, YouTube daily to see our highlights and helpful insights from our interviews on the podcast. Post a Review: you'll receive three free gifts when you post an honest review about Golf Smarter the podcast.Fill Out a Listener Survey: It only takes a few minutes to fill out our survey, which helps us to better serve your interests in the podcast. You'll receive a free link to Tony Manzoni's video and Justin Tang's summary of Tony's Lost Fundamental on pdf!This episode is brought to you by BreakfastBalls.Golf. Visit BreakfastBalls.Golf for the best quality and pricing on premium used golf balls. Find your favorite brand at half the price of new balls!  Use GOLFSMARTER at checkout for 20% off your order!This episode is brought to you by the Tour Striker Golf Academy. Visit tourstriker.com/TSGA and use the code GOLFSMARTER to get your first month of the Tour Striker GolfAcademy Online free, plus instant access to two bonus courses—'The Recipe for Better Golf' and 'Bombs: How to Consistently Smash the Driver”: a $194 value for free.This episode is brought to you by 5Hour Energy. 5-hour ENERGY Transfusion flavor is available online or in stores. Head to 5hourENERGY.com and order yours today!Check out "Invested in the Game", a new original podcast from Charles Schwab. This podcast is their way of sharing the incredible stories behind the game. Listen now at schwab.com/TheGame or wherever you get your podcasts.This episode is sponsored by Indeed. Please visit indeed.com/GOLFSMARTER and get a $75 SPONSORED JOB CREDIT. Terms and conditions apply.   

Cole Macedo steals some High Limit money, and then promptly crashed. Mike Marlar continues car swapping, McKay Wenger makes a change, Ricky Thornton Jr. races a lot, and more today.

Stupid News Extra 7-15-2025 ...No Instacart Driver would make that delivery

Part 1 The Energy Bus by Jon Gordon Summary"The Energy Bus: 10 Rules to Fuel Your Life, Work, and Team with Positive Energy" by Jon Gordon is a motivational book that tells the story of George, a man facing personal and professional challenges. As he navigates difficulties at work and in his family life, he encounters a mysterious bus driver named Joy who offers him a new perspective on life through ten fundamental rules for harnessing positive energy. Summary of Key Elements:The Journey Begins: George is frustrated with his job and his life. He feels overwhelmed by negativity, which affects both his attitude and his relationships.Meeting Joy: He boards the Energy Bus, driven by Joy, who introduces him to the concept of positive energy and how it can transform experiences and interactions.10 Rules Explained: Rule 1: You're the Driver of Your Bus – Take control of your own life and energy. Rule 2: Desire, Vision, and Focus – Determine what you want and have a clear vision to reach your goals. Stay focused and passionate. Rule 3: Fuel Your Ride with Positive Energy – Surround yourself with positive influences and eliminate toxic energy. Rule 4: Invite People on Your Bus – Share your vision with others who are positive and contribute to your journey. Rule 5: Don't Waste Your Energy on Those Who Don't Get on Your Bus – Learn to let go of negativity from those who aren't supportive. Rule 6: Post a Sign that Says "No Energy Vampires Allowed" – Protect your energy from those who siphon it away. Rule 7: Envision Your Destination – Continually visualize where you want to go and what you want to achieve. Rule 8: Train to Be a Positive Bus Driver – Develop and maintain a positive mindset through practice and discipline. Rule 9: Have Fun and Enjoy the Ride – Make sure to enjoy the process, as happiness and laughter are essential for energy. Rule 10: Give Your Bus Away – Share your positive experiences and knowledge with others to help them as well.Transformation: Throughout the bus ride, George learns to shift his mindset, bringing about positive changes in his life and inspiring those around him. The book illustrates how adopting a positive outlook can lead to improved relationships, better work environment, and overall fulfillment. Conclusion:"The Energy Bus" combines storytelling with actionable principles designed to motivate individuals both personally and professionally. It is a guide on embracing positivity and the importance of surrounding oneself with supportive people to overcome life's challenges.Part 2 The Energy Bus AuthorJon Gordon is an American author and speaker who is well known for his work in the fields of leadership, teamwork, and personal development. He released his popular book, "The Energy Bus: 10 Rules to Fuel Your Life, Work, and Team with Positive Energy," in 2007. The book uses a simple fable to emphasize the importance of a positive attitude and how it can lead to personal and professional success. Other Books by Jon GordonJon Gordon has written several other books that expand on various themes of positivity and motivation, including:"The Seed: Finding Purpose and Happiness in Life and Work" (2011)"The No Complaining Rule: Positive Ways to Deal with Negativity at Work" (2010)"Training Camp: What the Best Do Better Than Everyone Else" (2009)"The Power of a Positive Team: Proven Principles and Practices that Make Great Teams Great" (2018)"Stay Positive: A Kid's Guide to Maintaining a Positive Attitude" (2020)"The Coffee Bean: A Simple Lesson to Create Positive Change" (2019, co-authored with Damon West) Best EditionWhile opinions on the best book can vary based on personal preference and specific needs, many consider "The Energy Bus" to be Jon Gordon's flagship work, given...

Ryan is back on the podcast! After sharing his couples trip to Costa Rica last year on Episode 15, he returns with another couples summer getaway, this time to Placencia, Belize. The best part - this fabulous trip started as a school auction prize!In June 2025, Ryan and three other couples headed to a stunning vacation home in Belize complete with a private chef, daily laundry service, and even a personal boat driver who took them to dinner by sea. From snorkeling adventures to a BBQ on a private island, the group relaxed and enjoyed paradise.This episode is presented by Level 8 Luggage. Use code PreAS20 for 20% site-wide in July! I'm loving the 20-inch Luminous Carry On in Pink.Buy Me a CoffeeEarn free travel by applying for my favorite travel credit card, the Chase Sapphire Preferred, with my link!Mentioned in this episode:- Gecko Vacation Rentals in Belize- Island Time Gecko vacation rental home in Placencia, Belize- Belize City- Cessna Grand Caravan Turboprop Plane- Manatees- Restaurants: Barefoot Bar, Tipsy Tuna, Tutti Frutti Gelato, Omar's, Rum Fish, Placencia Yacht Club- Turtle Inn - A Francis Ford Coppola Hideaway- Snorkeling in Belize National Parks- Global Entry

This is the All Local morning update for July 14, 2025.

China's automotive companies have accelerated their global expansion in recent years, leaving the competition struggling to keep up. We explore what's driving Chinese brands' acceleration into international markets. And we look at how established carmakers are having to tighten their belts to compete with low-cost rivals.Some claim Chinese cars are a security risk because they could, in theory, be hacked - but could they really be used to spy on their owners? Presented and produced by Theo Leggett(Picture: BYD Yangwang U9 electric supercar on display during 2025 China Mobility Show at Hangzhou International Expo Center in Hangzhou, Zhejiang Province of China, June 2025. Credit: Getty Images)

James sits down and has an exclusive chat with IndyCar driver Christian Rasmussen. They chat about recent podium success, being a Danish racing driver, and the impact social media can have on a personal brand!

Savage discusses a shocking event that shaped Donald Trump's stance of crime when his elderly mother was mugged in Queens, New York in 1991. Savage explores how this event significantly contributed to Trump's views on criminal justice. He then weaves in personal anecdotes, including memories of his own mother, reflections on the second half of the 20th century, and experiences from his childhood and his radio career. Savage shares his famous "I've Seen" poem that reflects on the pivotal moments in history and societal changes he has witnessed in his lifetime. He offers insights on health, nutrition, and the importance of maintaining a robust life force. He concludes with a message on healing and the need to tap into the universal energy for well-being.

Ben Kapaldo and Greg Poehler in stuido with Johnny trying out for the Producer job. Steve Robinson got very emotional on Tucker Carlson (0:03:30). The state wants Kirk to go to Driver's education again (0:16:00). Kirk gives the reason why there is no Unnamed Show today and reacts to the Internet Invitational roster (0:21:00). Mut gives us an update on the UConn job (0:33:00). Taking Call (0:58:00). Alex Stein calls in to ask if bots are in the YouTube chat (1:28:00). Jeff D Lowe calls in with a proposition for Justin (2:00:00).You can find every episode of this show on Apple Podcasts, Spotify or YouTube. Prime Members can listen ad-free on Amazon Music. For more, visit barstool.link/kminshow